Answers are grounded in this paper and cite their sources.
Topical roflumilast (ROF) is a recently approved phosphodiesterase 4 inhibitor for the treatment of psoriasis. It has strong anti-inflammatory effects which are quite helpful in the management of the distressing symptoms of psoriasis, as seen in several clinical trials. It also displayed a wide range of safety and, hence, can be utilized in patients without fearing the advent of any dangerous side effects. However, more clinical data are required to find out the extended properties of this molecule and future applications in other dermatological conditions. In 2011, oral ROF (Daliresp®) received Food and Drug Administration (FDA) approval for patients with severe chronic obstructive pulmonary disease and recurrent exacerbations. More recently, in 2022, topical ROF 0.3% cream (Zorvye™) obtained FDA approval for the management of plaque psoriasis in patients aged 12 years and older.
No takes yet. Share an insight, caveat, or question.
De et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: